期刊文献+

微小残留白血病检测在急性髓系白血病治疗及预后判断中的意义及研究进展 被引量:3

原文传递
导出
摘要 急性髓系白血病(AML)是较为常见的造血系统恶性克隆性疾病。虽然目前临床应用大剂量化疗和干细胞移植等手段取得了一定的疗效,可延长部分患者无病生存期,但是恶性疾病易复发的特点使得其长期生存率依旧很低。微小残留白血病(MRL)是导致白血病复发的重要原因,若能及时发现残留病变并施加相应的临床干预,对于减少缓解后复发,改善白血病预后将提供极大的帮助。目前,尚无对MRL的统一标准定义,但现有的技术可以在一定程度上对MRL进行相关指标的检测,利用多参数流式细胞技术(MFC)以及实时荧光定量PCR(RQ-PCR)等手段可监测MRL,这对MRL明确诊断后治疗决策的选择以及治疗后预后判断均有重要意义。现就MRL相关指标的检测在AML治疗及预后判断中的研究及应用进展作一综述。
出处 《国际输血及血液学杂志》 CAS 2013年第2期133-135,共3页 International Journal of Blood Transfusion and Hematology
  • 相关文献

参考文献18

  • 1Lo wenberg G. Strategies in the treatment of acute myeloid leukemia. Haematologica, 2004, 89(9) :1029-1032.
  • 2Suciu S, Mandelli F, Witte T, et al. Allogeneic compared with autologous stem cell transplantation in the treatment of patients younger than 46 years with acute myeloid leukemia (AML) in first complete remission (CR1) : an intention-to- treat analysis of the EORTC/GIMEMAAML-10 trial. Blood, 2003,102(4) : 1232- 1240.
  • 3Burnett AK, Goldstone AH, Stevens RM, et al. Randomised comparison of addition of autologous bone marrow transplantation to intensive chemotherapy for acute myeloid leukemia in first remission : results of MRC AML10 trial. UK Medical Research Council Adult and Children: s Leukemia Working Parties. Lancet, 1998, 351(9104): 700-708.
  • 4Buccisano F, Maurillo L, Del Principe M,et al. Prognostic and therapeutic implications of minimal residual disease detection in acute myeloid leukemia. Blood, 2012, 119(2) :332-341.
  • 5Dinardo CD, Luger SM. Beyond morphology: minimal residual disease detection in acute myeloid leukemia: Curr Opin Hematol, 2012, 19(2) :82-88.
  • 6陈琳军,丁训杰.微量残留白血病检测方法研究进展[J].肿瘤,1998,18(2):118-120. 被引量:3
  • 7Grimwade D, Vyas P, Freeman S . Assessment of minimal residual disease in acute myeloid leukemia. Curr Opin Oncol, 2010, 22(6):656-663.
  • 8Lacombe F, Arnoulet C, Maynadi6 M,et al. Early clearance of peripheral blasts measured by flow cytometry during the first week of AML induction therapy as a new independent prognostic {actor: a GOELAMS study. Leukemia,2009,23(2):350-357.
  • 9Shook D, Coustan-Smith E, Ribeiro RC, et al. Minimal residual disease quantitation in acute myeloid leukemia. Clin Lymphoma Myeloma,2OO9,9(Suppl 3) :$281-$285.
  • 10Santamaria C, Chitl6n MC, Ferndndez C, et al. Using quantification of the PML-RAR alpha transcript to stratify the risk of relapse in patients with acute promyelocytic leukemia. Haematologica, 2007, 92(3):315-322.

共引文献2

同被引文献19

  • 1吴铭,孙雄飞,徐肇明,张新友,李富荣,王兴根,陈晓琳,林海清,文鸿光,孙璇,宋通微.基于细胞表型异常的流式细胞术检测急性前体B细胞白血病微小残留病[J].中国实验血液学杂志,2005,13(4):557-562. 被引量:4
  • 2Jin J,Wang JX, Chen FF,et al. Homoharringtonine-based induction regi- mens for patients with de-novo acute myeloid leukaemia:a multicentre, open-label ,randomised,eontrolled phase 3 trial[J]. Lancet Oneol,2013,14(7):599-608.
  • 3Mr6zek K, Marcucci G,Paschka P,et al. Clinical relevance of mutations and gene-expression changes in adult acute myeloid leukemia with nor- malcytogenetics:are we ready for a prognostically prioritized molecular classification[J]. Blood, 2007,109 ( 2 ) : 431-448.
  • 4Graubert T, Walter MJ. Genetics of myelodysplastic syndromes : new in- sights[J]. Hematol Am Soc Hematol Educ Program,2011,2011:543-549.
  • 5Brtiggemann M, Raft T, Flohr T, et al. Clinical significance of minimal residual disease quantification in adult patients with standard-risk acute lymphoblastic leukemia[J]. Blood, 2006,107 (3) : 1116-1123.
  • 6Holowiecki J, Krawczyk-Kulis M, Giebel S,et al. Status of minimal residual disease after induction predicts outcome in both standard and high-risk Ph-negativeadult acute lymphoblastic leukaemia. The Polish Adult Leu- kemia Group ALL 4-2002 MRD Study[J]. Br J Haemato1,2008,142 (2) : 227-237.
  • 7Kern W, Bacher U, Haferlach C, et al. The role of multiparameter flow cy- tometry for disease monitoring in AML[J]. Best Pract Res Clin Haematol, 2010,23(3) :379-390.
  • 8Dworzak MN ,Fr~schl G,Printz D ,et al. Prognostic significance and mo- dalities of flow cytometric minimal residual disease detection in childhood acute lymphoblastic leukemia[J]. Blood, 2002,99 (6) : 1952-1958.
  • 9San Miguel JF, Vidriales MB, L6pez-Berges C, et al. Early immunopheno- typical evaluation of minimal residual disease in acute myeloid leukemia identifies differentpatient risk groups and may contribute to postinduction treatment stratification[J]. Blood, 2001,98 ( 6 ) : 1746-1751.
  • 10Buccisano F, Manrillo L, Gattei V,et al. The kinetics of reduction of mi- nimal residual disease impacts on duration of response and survival of patients with acute myeloid leukemia[J]. Leukemia, 2006,20 (10) : 1783- 1789.

引证文献3

二级引证文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部